UK regenerative medicine companies are being offered the opportunity to compete for an investment package designed to enable them to boost their productivity. The government-backed Technology Strategy Board has launched a £1.5m collaborative R&D competition call, setting businesses the challenge of developing a better understanding of the best ways to make a profit from regenerative medicine.
Zahid Latif, Lead Technologist in Biosciences, Medicines and Healthcare for the Technology Strategy Board said:
“Regenerative medicine companies operate in an emerging business sector, in an international environment where delivery of regenerative medicine could take on a number of different guises as the products and services are developed. The number of UK companies working in this field has been growing since 2003 and we are a world leader in this area, with a strong academic science base and a supportive clinical and regulatory environment.”
“There has been much recent progress but if the UK is to fulfill its potential, there are a number of development challenges which need to be overcome to successfully commercialize promising discoveries,” he added.
The competition is designed to encourage businesses to explore where and how value is created in the regenerative medicine value chain and develop business models to enable them to best capture that value, for themselves and the UK economy as a whole.
The Technology Strategy Board is a business-led executive nondepartmental public body, established by the government. Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business to increase economic growth and improve the quality of life. It is sponsored by the Department for Business, Innovation and Skills (BIS). For more information visit www.innovateuk.org.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.